$PRTA
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aร-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
Healthcare
Sector
Biotechnology
Industry
Gene G. Kinney
CEO
163
Employees
$8.28
Current Price
$494.70M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 1 | 2 | $920,049.00 | 110,000 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 1 | 4 | $2,741,103.00 | 325,000 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 1 | 8 | $6,737,349.30 | 790,500 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 2 months | Buys | 1 | 10 | $7,432,517.90 | 867,500 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 3 months | Buys | 1 | 12 | $7,755,737.90 | 905,000 | 57.04:1 |
| Sells | 2 | 2 | $135,974.78 | 16,048 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Oct 14, 2026 | SCULLY WILLIAM P 10% Owner | Purchase | 10,000 | $8.46 | $84,569.00 | View Details |
| Oct 13, 2026 | SCULLY WILLIAM P 10% Owner | Purchase | 100,000 | $8.35 | $835,480.00 | View Details |
| Oct 7, 2026 | SCULLY WILLIAM P 10% Owner | Purchase | 125,000 | $8.40 | $1,050,150.00 | View Details |
| Oct 8, 2026 | SCULLY WILLIAM P 10% Owner | Purchase | 90,000 | $8.57 | $770,904.00 | View Details |
| Oct 2, 2026 | SCULLY WILLIAM P 10% Owner | Purchase | 100,000 | $8.57 | $857,240.00 | View Details |
| Sep 29, 2026 | SCULLY WILLIAM P 10% Owner | Purchase | 162,000 | $8.68 | $1,405,674.00 | View Details |
| Sep 28, 2026 | SCULLY WILLIAM P 10% Owner | Purchase | 103,500 | $8.60 | $889,872.30 | View Details |
| Sep 18, 2026 | SCULLY WILLIAM P 10% Owner | Purchase | 100,000 | $8.43 | $843,460.00 | View Details |
| Sep 2, 2026 | SCULLY WILLIAM P 10% Owner | Purchase | 27,000 | $9.47 | $255,738.60 | View Details |
| Aug 20, 2026 | SCULLY WILLIAM P 10% Owner | Purchase | 50,000 | $8.79 | $439,430.00 | View Details |
| Aug 7, 2026 | SCULLY WILLIAM P 10% Owner | Purchase | 3,500 | $8.62 | $30,167.20 | View Details |
| Aug 7, 2026 | SCULLY WILLIAM P 10% Owner | Purchase | 34,000 | $8.62 | $293,052.80 | View Details |
| Jul 29, 2026 | Kingston Anne Evans Chief Strategy Officer | Sale | 7,662 | $8.47 | $64,919.36 | View Details |
| Jul 29, 2026 | Isaacs Michael John General Counsel&Company Sec. | Sale | 8,386 | $8.47 | $71,055.42 | View Details |
6 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
EPS
Estimated-$0.21
ActualN/A
Revenue
Estimated$9.58M
ActualN/A
Past Earnings
Historical earnings results
No earnings data in the last 3 months. Sign up free to see 12 months of history.